Ziprasidone and the pharmacokinetics of a combined oral contraceptive

British Journal of Clinical Pharmacology

Volumn 49, Issue SUPPL. 1, 2000, Pages 49-56

  Muirhead, G J ^a   Harness, J ^a   Holt, P R ^b   Oliver, S ^c   Anziano, R J ^d  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c Besselaar Clinical Research Unit   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Contraceptive; Ethinyloestradiol; Interaction; Levonorgestrel; Pharmacokinetics; Ziprasidone

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROLACTIN; ZIPRASIDONE;

ADULT; AGITATION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DREAMING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SIDE EFFECT; SOMNOLENCE;

EID: 0034094023     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00153.x     Document Type: Article

References (20)

1. Kulkarni J. Women and schizophrenia: a review. Austr NZ J Psychiatry 1997; 31: 46-56.
2. Häfner H, van der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997; 42: 139-151.
3. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr 1992; 20(Suppl): 1-97.
4. Kendler KS, Walsh D. Gender and schizophrenia: results of an epidemiologically based family study. Br J Psychiatry 1995; 167: 184-192.
5. Seeman MV, Lang M. The role of oestrogens in schizophrenia: gender differences. Schizophr Bull 1990; 16: 185-195.
6. Fink G, Sumner BE, Rosie R, et al. Estrogen control of central mood, mental state and memory. Cell Mol Neurobiol 1996; 16: 325-344.
7. Banck DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokin 1990; 18: 472-484.
8. Pichard L, Fabre G, Fabre J, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary human hepatocytes and liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
9. Smith DA. Species differences in metabolism and pharmacokinetics: are we close to understanding? Drug Metab Rev 1991; 23: 355-373.
10. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform responsible for the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49(Suppl. 1): 35S-42S.
11. Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 1988; 50: 876-881.
12. Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
13. Dickson RA, Dalby JT, Williams R, et al. Risperidon-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995; 152: 1102-1103.
14. Ananthamoorthy R, Caracci G. Prolactin levels of premenopausal women treated with risperidone and conventional neuroleptics. Presented at the 150th Annual Meeting of the American Psychiatric Association (APA), San Diego, USA, 17-22 May, 1997, NR 164.
15. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 5S-13S.
16. King DJ, Devaney N, Cooper SJ. Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients. J Psychopharmacol 1990; 2: 83-89.
17. Lahdelma RL, Appelberg B, Kuoppasalmi K, et al. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. Eur Neuropsychopharmacol 1991; 1: 535-540.
18. Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19: 603-606.
19. Seeger TF, Seymour AW, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-113.
20. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 15S-20S.